Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Q1 FY2026 Earnings Presentation
18 slides from Piramal Pharma's earnings presentation, July 2025
Slide 1: Q1FY26 Results
Q1FY26 Results Piramal july 2025 Pharma Limited
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation, directly or indirectly, in any manner,
Slide 3: Key Highlights of the Quarter – Q1FY2026
Key Highlights of the Quarter – Q1FY2026 Revenue from Operations EBITDA & EBITDA Margin Historically, H2 has Outperformed H1 (In ₹ Crore) (EBITDA: In ₹ Crore) EBITDA Margin % of Full Year Revenue H1 H2 1% 11% 9% 55 55 54 45 45 46 FY23 FY24 FY25 % of Full Year EBITDA 1,951 1,934 224 165 64 65 60 36 3
Slide 4: Business Wise Performance
Business Wise Performance
Slide 5: CDMO Business
CDMO Business Performance Highlights Revenue Growth (In ₹ Crore) ❖ Excluding the impact of destocking in one large product, the remaining CDMO business grew at mid-teen rate 6% • The growth was primarily led by the overseas facilities with YoY improvement in their profitability • Nutrition Supplemen
Slide 6: Groundbreaking Ceremony at Lexington (US)
Groundbreaking Ceremony at Lexington (US) Investing US$ 90 million to expand two of our US facilities, Lexington and Riverview. Working synergistically, they will play a vital role in our integrated ADC development and manufacturing program, branded ADCelerate™. On June 25, 2025, we marked a key mil
Slide 7: Complex Hospital Generics Business
Complex Hospital Generics Business Performance Highlights Revenue Growth (In ₹ Crore) ❖ Inhalation Anesthesia – Slower growth in Q1FY26 due to phasing of institutional 1% orders. Expect growth to pick up in the remaining part of the financial year • Slower growth in the key market of US, partly offs
Slide 8: Piramal Consumer Healthcare Business
Piramal Consumer Healthcare Business Performance Highlights Revenue Growth ❖ New Product launches - 7 new products launched in Q1FY26. Products launched in (In ₹ Crore) last 24 months contributed 8% to PCH sales in FY25 15% 302 ❖ Power Brands grew 18% YoY during Q1FY26, contributing 49% to total PCH
Slide 9: Focus on Power Brands with Brand Promotion and Marketing
Page 9 Focus on Power Brands with Brand Promotion and Marketing (In ₹ Cr) Investments in Brand Promotion and Marketing % of PCH 15% 13% 11% 13% 13% sales Little’s Tetmosol CIR 131 131 125 Wipes, Toys, Diapers, Medicated Soap, Adult Diapers, 38 33 Feeding Range Cream & Powder Bed Bath Wipes FY23 FY24
Slide 10: Abbvie Therapeutics India Private Limited
Page 10 Abbvie Therapeutics India Private Limited Joint Venture Arrangement Ownership Ownership 49% 51% In FY2025, the JV reported1 revenue of ₹493 Cr. with PAT margin of 28% Continue to be one of the Strong presence in 400+ Key Brands market leaders glaucoma, dry Refresh, Ozurdex, in the Indian emp
Slide 11: Financials
Financials
Slide 12: Consolidated Financials Highlights
Consolidated Financials Highlights (in ₹ Cr. or as stated) Particulars Q1FY26 Q1FY25 % Change Revenue from Operations1 1,934 1,951 (1)% CDMO 997 1,057 (6)% CHG 637 631 1% PCH 302 263 15% EBITDA 165 224 (26)% EBITDA Margin 9% 11% PAT (after exceptional item) (82) (89) 8% 1. Revenue from Operations in
Slide 13: Reiterating our FY2030 Aspirations
Reiterating our FY2030 Aspirations
Slide 14: Financial Aspirations for FY2030
Financial Aspirations for FY2030 3x 2x 1x Over 3x Growth in More than Double the Reduce Leverage EBITDA Revenues on the Balance Sheet ~25% US$2+ Bn ~1x EBITDA Margins Revenue Net debt to EBITDA Exponential Growth Enhance ROCE in PAT Early Teens PAT Margins High Teens ROCE Note:- The aspirations ment
Slide 15: US$2+ Bn Company with 25% EBITDA Margin by FY2030
US$2+ Bn Company with 25% EDITDA Margin by FY2030 Strategic Goals for FY2030 US$1.2 Bn revenues with ~25% US$600 Mn revenues with 25%+ US$200 Mn revenues with double-digit EBITDA margin EBITDA margin EBITDA margin CDMO CHG PCH Emerge as a fast-growing, innovation- Become a leading critical care comp
Slide 16: Key Investment Highlights
Key Investment Highlights US$2+ Bn Global Pharma, Health & Wellness Company by FY2030 1 Strong promoter group with over 35 years of demonstrated ability to build scalable and differentiated businesses 2 Presence in large multi-billion dollar size attractive industry segments with promising tailwinds
Slide 17: Dial-in Details for Q1FY26 Earnings Conference Call
Dial-in Details for Q1FY26 Earnings Conference Call Event Location & Time Telephone Number +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) India – 09:30 AM IST 1 800 120 1221 (Toll free number) USA – 12:00 AM Toll free number Conference call (Eastern Time – New York) 18667462133 on 29th July 20
Slide 18: For Investor Queries
For Investor Queries: Gagan Borana Madhusudan Dalmia Investor Relations and Enterprise Risk Management Investor Relations Email: gagan.borana@piramal.com Email: madhusudan.dalmia@piramal.com Our Websites:- Piramal Pharma Limited CDMO www.piramalpharma.com www.piramalpharmasolutions.com Complex Hospi